1. Allison, A.C. and Byars, N.E., 1986, An adjuvant formulation that selectively elicits the formation of antibodies of protective isotype and cell mediated immunity, J.Immunol.Methods,95:157.
2. Allison, A.C. and Byars, N.E., 1987, Vaccine technology: Adjuvants for increased efficiency, Biotechnol., 5:1041.
3. Bejarano, M.T., Masucci, M.G., Morgan, A., Morein, B., Klein, E. and Klein, G., 1990, Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts, and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation, J.Virol., 64:1398.
4. Burkitt,D., 1963, A lymphoma syndrome in tropical Africa, in: “InternationalReview of Experimental Pathology”, Vol. 2, G.W. Richter and M.A. Epstein, eds.
5. Churchill, A.E., Payner, L.N. and Chubb, R.C., 1969, Immunization against Marek!s disease using a live attenuated virus, Nature, 221:744.